Registry of Lobbyists
Version 4 of 35 (2008-06-25 to 2009-07-06) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
Eli Lilly Canada Inc.
3650 Danforth Avenue Toronto, ON M1N 2E8 Canada |
| Telephone number: | 416-699-7222 |
| Fax number: | 416-694-0487 |
| Responsible officer name and position during the period of this registration: | David Ricks, President and General Manager |
| Description of activities: | Pharmaceutical manufacturer, research and development, commercial operations. |
| Parent: | The corporation is not a subsidiary of any other parent corporations. |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: |
BIOTECANADA
(Partner) 420 - 130 ALBERT STREET OTTAWA, ON Canada K1P 5G4 Elanco Animal Health 150 Research Park Lane, Suite 120 Guelph, ON Canada N1G 4T2 Rx & D, Canada's Research-Based Pharmaceutical Companies (Partner) 55 Metcalfe Street, Suite 1220 Ottawa, ON Canada K1P 6L5 |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | D.Terrence McCool |
| Position title: | Vice President, Corporate Affairs |
| Public offices held: | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Aboriginal Affairs and Northern Development Canada, Canadian International Development Agency (CIDA), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO) | ||||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||
| Subject Matter: Areas of Concern: | Health, Industry, Intellectual Property, International Trade, Science and Technology, Taxation and Finance | ||||||||
| Subject Matter: Retrospective: | General information sharing with Health Canada, Industry Canada on Health policy issues and intellectual property | ||||||||
| Subject Matter: Prospective: | Intellectual Property Data protection and changes to Patented Medicine Notice of compliance (PMNOC) linkage regulationsHealth Canada - National Pharmaceutical strategy Patented Medicine Prices Review Board (PMPRB), Food & Drug Act changes (Bill C51) | ||||||||
Details Regarding the Identified Subject Matter
|
|||||||||